(Q30148670)

English

A systematic review and meta-analysis of cross-reactivity of antibodies induced by oil-in-water emulsion adjuvanted influenza H5N1 virus monovalent vaccines

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

7 June 2017

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

Europe PubMed Central

A systematic review and meta-analysis of cross-reactivity of antibodies induced by oil-in-water emulsion adjuvanted influenza H5N1 virus monovalent vaccines (English)

1 reference

Europe PubMed Central

7 June 2017

author name string

Kinnera E Chada

1

1 reference

Europe PubMed Central

7 June 2017

Richard Forshee

2

1 reference

Europe PubMed Central

7 June 2017

Hana Golding

3

1 reference

Europe PubMed Central

7 June 2017

Steven Anderson

4

1 reference

Europe PubMed Central

7 June 2017

Hong Yang

5

1 reference

Europe PubMed Central

7 June 2017

language of work or name

0 references

publication date

5 May 2017

1 reference

Europe PubMed Central

7 June 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

7 June 2017

35

1 reference

Europe PubMed Central

7 June 2017

24

1 reference

Europe PubMed Central

7 June 2017

3162-3170

1 reference

Europe PubMed Central

7 June 2017

Aflunov®: a vaccine tailored for pre-pandemic and pandemic approaches against influenza

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

Airborne transmission of influenza A/H5N1 virus between ferrets

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

Transmission of influenza A/H5N1 viruses in mammals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

Pre-pandemic and pandemic influenza vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

Assessment of antigen-specific and cross-reactive antibody responses to an MF59-adjuvanted A/H5N1 prepandemic influenza vaccine in adult and elderly subjects

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

Vaccines against epidemic and pandemic influenza

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

H5N1 Avian influenza: preventive and therapeutic strategies against a pandemic.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

Progress with human H5N1 vaccines: a perspective from industry.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

Immunogenicity and adverse events of avian influenza A H5N1 vaccine in healthy adults: multiple-treatments meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

Effectiveness and harms of seasonal and pandemic influenza vaccines in children, adults and elderly: a critical review and re-analysis of 15 meta-analyses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

Safety and immunogenicity of prepandemic H5N1 influenza vaccines: a systematic review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

Corrigendum to “Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: Results of a randomised single heterologous booster dose

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

Aflunov(®): a prepandemic influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

An assessment of prime-boost vaccination schedules with AS03A -adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

Graphical augmentations to the funnel plot assess the impact of additional evidence on a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

A phase III, randomized, open-label study to assess the tolerability and immunogenicity of an H5N1 influenza vaccine administered to healthy adults with a 1-, 2-, 3-, or 6-week interval between first and second doses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

Rapid immunization against H5N1: a randomized trial evaluating homologous and cross-reactive immune responses to AS03(A)-adjuvanted vaccination in adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

A phase II, open-label, multicentre study to evaluate the immunogenicity and safety of an adjuvanted prepandemic (H5N1) influenza vaccine in healthy Japanese adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

Safety and immunogenicity of a split-virion AS03A-adjuvanted A/Indonesia/05/2005 (H5N1) vaccine in Taiwanese adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults: a phase IV, randomized, open-label, controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

Outlier and influence diagnostics for meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 influenza viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

Impact of preexisting memory to seasonal A/H1N1 influenza virus on the immune response following vaccination against avian A/H5N1 virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

Immunogenicity and cross-reactivity of 2009-2010 inactivated seasonal influenza vaccine in US adults and elderly

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

Kinetics and longevity of antibody response to influenza A H5N1 virus infection in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

Homologous and heterologous antibody responses to a one-year booster dose of an MF59(®) adjuvanted A/H5N1 pre-pandemic influenza vaccine in pediatric subjects

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

Strategies for mitigating an influenza pandemic

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

Heterologous prime-boost vaccination with MF59-adjuvanted H5 vaccines promotes antibody affinity maturation towards the hemagglutinin HA1 domain and broad H5N1 cross-clade neutralization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in adults 65years of age and older: A phase II, observer-blind, randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

AS03-adjuvanted H7N1 detergent-split virion vaccine is highly immunogenic in unprimed mice and induces cross-reactive antibodies to emerged H7N9 and additional H7 subtypes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2017.04.029

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2017.04.029

1 reference

Europe PubMed Central

7 June 2017

1 reference

Europe PubMed Central

7 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30148670&oldid=1967430997"